Company
DELiver Therapeutics
Applying high throughput DNA encoded library (DEL) drug screening in novel ways to deliver small molecule therapeutics that are both best-in-class and first-in-class, addressing some of the most difficult clinical challenges in cancer medicine
- Status
- Operatingas of 2026-09-19
- Business model
- B2B
- Legal name
- DELiver Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
Developing small molecule therapeutics that are both best-in-class and first-in-class, addressing some of the most difficult clinical challenges in medicine
Funding snapshot
- Total raised
- $3MSum of rounds, as of 2026-09-19Source (opens in a new tab)
- Latest round
- Convertible note, $3M
Funding rounds
- Convertible note
- $3MCompany stated
Loading relationship preview